Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$3.08
-$0.13(-4.22%)
At close: 4:00 PM EDT
$3.08
-$0.13(-4.22%)
Day’s Range― - ―
52-Week Range$2.12 - $42.00
Previous CloseN/A
Volume71.33K
Average Volume (3M)6.80M
Market Cap
$8.11M
Enterprise Value$14.17
Total Cash (Recent Filing)$8.12M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 17, 2026EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.98
Shares Outstanding2,806,701
10 Day Avg. Volume88,929
30 Day Avg. Volume6,795,886
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.50Price Target Upside1344.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-5.67
Revenue Forecast (FY)$6.37M
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ValidationFDA clearance is a durable validation that reduces regulatory barriers to hospital adoption, supports payer conversations, and amplifies physician interest. Coupled with independent study data, it increases the odds of sustained procedure volume growth and broader international market engagement over 2–6 months.
Growing U.S. Commercial Traction And Installed BaseA rising install base creates a recurring consumables runway (disposables and accessories) and improves visibility into follow-on system sales. Expanding active accounts and Q1 revenue growth reflect improving commercial execution that should compound into steady procedure-driven revenue over the medium term.
Low Leverage And Positive Equity BufferMinimal debt reduces near-term solvency risk and preserves financial flexibility for follow-on fundraising or operational ramp. A positive equity base supports continued access to capital markets and shields the company from immediate creditor pressure while commercial scale-up proceeds over coming quarters.
Bears Say
Large And Persistent Cash BurnCash burn far exceeds current revenue, so operations are not self‑funding; this creates ongoing reliance on external financing. Over several quarters this elevates dilution and execution risk, constrains marketing/sales investment pacing, and can force reprioritization if capital access tightens.
Reimbursement Timing UncertaintyUncertain physician reimbursement timing and conditional pass‑through status materially affect economics for providers and patient access. Delayed or limited reimbursement can slow office‑based adoption and lengthen conversion timelines, reducing predictable revenue scaling over the next 6–12 months.
Legal And Capital‑structure RisksA certified class action increases potential contingent liabilities and distracts management, while recent warrant amendments and ATM financing activity indicate ongoing reliance on external capital. Together these factors heighten dilution, governance scrutiny, and refinancing risk during the commercial ramp.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $2.12 and its highest was $42.00 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $8.11M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 14 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on May 12, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.4 by -$0.4.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -1.52.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 2,806,701 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
ICCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$44.50
▲(1344.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.44% Mutual Funds
0.71% Other Institutional Investors
97.85% Public Companies and
Individual Investors